Novacyt (NCYT) EUR0.0667 (CDI)
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Novacyt recovers £12.2m in VAT after settling DHSC dispute
22 August 2024 12:29
(Sharecast News) - Molecular diagnostics company Novacyt announced the successful recovery of £12.2m in VAT from HM Revenue and Customs (HMRC) on Thursday.
-
Novacyt settles High Court dispute with DHSC
11 June 2024 08:05
(Sharecast News) - Biotechnology group Novacyt and the UK's Department of Health and Social Care have reached a commercial settlement of all claims and counterclaims in High Court proceedings.
-
Novacyt gearing up for hearing in DHSC litigation
19 April 2024 11:02
(Sharecast News) - Molecular diagnostics specialist Novacyt updated the market on legal proceedings between itself and its subsidiary Primer Design against the Department of Health and Social Care (DHSC) on...
-
Novacyt confirms end of Yourgene Taiwan disposal discussions
6 February 2024 12:48
(Sharecast News) - Novacyt announced on Tuesday that it had received formal notification from INEX Innovate terminating discussions around the acquisition of Yourgene Health Taiwan.
-
Novacyt taps Steve Gibson for CFO
2 January 2024 08:12
(Sharecast News) - Biotechnology group Novacyt has appointed Steve Gibson to the role of chief financial officer with immediate effect.
-
Novacyt facing delays in disposal of Yourgene Taiwan
21 December 2023 15:49
(Sharecast News) - Molecular diagnostics company Novacyt updated the market on the conditional disposal of its laboratory in Taiwan, which it acquired as part of its purchase of Yourgene Health on 8 September.
-
Novacyt to buy Yourgene Health in £16.7m deal
3 July 2023 09:07
(Sharecast News) - Yourgene Health surged on Monday after it agreed to be bought by Novacyt in a £16.7m deal.
-
UK regulator approves Novacyt Covid-19 test
6 December 2022 12:29
(Sharecast News) - Shares in clinical diagnostics specialist Novacyt sparked on Tuesday, after the UK regulator approved its latest Covid-19 test.
-
Novacyt's exsig Covid-19 PCR test receives UK approval
15 July 2022 08:43
(Sharecast News) - Clinical diagnostics group Novacyt's exsig Covid-19 Direct Real-Time PCR test has received approval from the UK's Health Security Agency.
-
Novacyt gets another Covid-19 test approved in the UK
17 February 2022 15:38
(Sharecast News) - Clinical diagnostics company Novacyt announced on Thursday that its 'PROmate' Covid-19 2G Real-Time PCR test had been approved in the UK, under the UK Health Security...
Company announcements Announcements
-
Change of Registered Office
10 December 2024 07:00
Novacyt S.A. (CDI)
-
Further expansion of cost reduction programme
14 November 2024 13:20
Novacyt S.A. (CDI)
-
Liquidity Agreement and Total Voting Rights
1 November 2024 12:45
Novacyt S.A. (CDI)
-
Directorate Change
31 October 2024 07:00
Novacyt S.A. (CDI)
-
IVDR accreditation
17 October 2024 07:00
Novacyt S.A. (CDI)
-
Closure of IT-IS International
8 October 2024 12:30
Novacyt S.A. (CDI)
-
Liquidity Agreement and Total Voting Rights
1 October 2024 12:30
Novacyt S.A. (CDI)
-
Interim Results
26 September 2024 07:01
Novacyt S.A. (CDI)
-
Directorate Change
26 September 2024 07:00
Novacyt S.A. (CDI)
-
Rule 19.6(c) confirmation of post-offer intentions
20 September 2024 17:30
Novacyt S.A. (CDI)
-
Notice of Results
12 September 2024 07:00
Novacyt S.A. (CDI)
-
Liquidity Agreement and Total Voting Rights
2 September 2024 13:30
Novacyt S.A. (CDI)
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.